Cargando…
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644045/ https://www.ncbi.nlm.nih.gov/pubmed/19174571 http://dx.doi.org/10.1093/rheumatology/ken488 |
_version_ | 1782164705072119808 |
---|---|
author | Hachulla, Eric Carpentier, Patrick Gressin, Virginie Diot, Elisabeth Allanore, Yannick Sibilia, Jean Launay, David Mouthon, Luc Jego, Patrick Cabane, Jean de Groote, Pascal Chabrol, Amélie Lazareth, Isabelle Guillevin, Loïc Clerson, Pierre Humbert, Marc |
author_facet | Hachulla, Eric Carpentier, Patrick Gressin, Virginie Diot, Elisabeth Allanore, Yannick Sibilia, Jean Launay, David Mouthon, Luc Jego, Patrick Cabane, Jean de Groote, Pascal Chabrol, Amélie Lazareth, Isabelle Guillevin, Loïc Clerson, Pierre Humbert, Marc |
author_sort | Hachulla, Eric |
collection | PubMed |
description | Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the Kaplan–Meier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 ± 13.0 years and mean duration of SSc of 8.8 ± 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening. |
format | Text |
id | pubmed-2644045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26440452009-02-25 Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study Hachulla, Eric Carpentier, Patrick Gressin, Virginie Diot, Elisabeth Allanore, Yannick Sibilia, Jean Launay, David Mouthon, Luc Jego, Patrick Cabane, Jean de Groote, Pascal Chabrol, Amélie Lazareth, Isabelle Guillevin, Loïc Clerson, Pierre Humbert, Marc Rheumatology (Oxford) Clinical Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the Kaplan–Meier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 ± 13.0 years and mean duration of SSc of 8.8 ± 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening. Oxford University Press 2009-03 2009-01-27 /pmc/articles/PMC2644045/ /pubmed/19174571 http://dx.doi.org/10.1093/rheumatology/ken488 Text en © 2009 The Author(s) http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Hachulla, Eric Carpentier, Patrick Gressin, Virginie Diot, Elisabeth Allanore, Yannick Sibilia, Jean Launay, David Mouthon, Luc Jego, Patrick Cabane, Jean de Groote, Pascal Chabrol, Amélie Lazareth, Isabelle Guillevin, Loïc Clerson, Pierre Humbert, Marc Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title_full | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title_fullStr | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title_full_unstemmed | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title_short | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study |
title_sort | risk factors for death and the 3-year survival of patients with systemic sclerosis: the french itinérair-sclérodermie study |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644045/ https://www.ncbi.nlm.nih.gov/pubmed/19174571 http://dx.doi.org/10.1093/rheumatology/ken488 |
work_keys_str_mv | AT hachullaeric riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT carpentierpatrick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT gressinvirginie riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT diotelisabeth riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT allanoreyannick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT sibiliajean riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT launaydavid riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT mouthonluc riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT jegopatrick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT cabanejean riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT degrootepascal riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT chabrolamelie riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT lazarethisabelle riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT guillevinloic riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT clersonpierre riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT humbertmarc riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy AT riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy |